Author of the publication

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors

, , and . J Mol Diagn, 18 (3): 350-361 (May 2016)
DOI: 10.1016/j.jmoldx.2015.11.009

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial, , , , , , , , , and 19 other author(s). JAMA, 318 (23): 2306-2316 (December 2017)Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial, , , , , , , , , and 14 other author(s). Eur J Cancer, (May 2018)Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study, , , , , , , , , and 27 other author(s). Lancet Oncol, 17 (11): 1521-1532 (November 2016)Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide, , , , , , , , , and . Clin Cancer Res, 10 (6): 1871-1874 (March 2004)Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors, , and . J Mol Diagn, 18 (3): 350-361 (May 2016)